Trial · NCT01342445
Effects of LDX on Functioning of College Students With ADHD
NCT01342445, Phase 4, Completed, University of Rhode Island; results first posted 2014-04-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of LDX on Functioning of College Students With ADHD. Trials, record NCT01342445. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01342445
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of LDX on Functioning of College Students With ADHD
- NCT number
- NCT01342445
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 50 participants, actual
- Lead sponsor
- University of Rhode Island
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- lisdexamfetamine dimesylate, Placebo
- First posted
- 2011-04-27
- Last updated
- 2025-04-24
- Results first posted
- 2014-04-08
- Limitations and caveats
- No notable limitations or caveats are noted.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Conners Adult ADHD Rating Scale - Short Version (CAARS) | after receiving Placebo or LDX for 1 week | CAARS ADHD Index, adult self-report measure of ADHD symptoms. T-scores (mean = 50; standard deviation = 10) for all subscales on the short version were used as dependent measures with higher scores representing greater ADHD symptomatology (and ultimately a worse outcome in this study). |
| Primary | Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | after receiving Placebo or LDX for 1 week | BRIEF-A is a standardized self-report measure that captures adults' views of their own self-regulation in their everyday environment. Metacognition Index T-scores (mean = 50; standard deviation = 10) were used as dependent measures with higher scores representing greater deficit in planning/organizational skills critical for college success. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Conners Adult ADHD Rating Scale - Short Version (CAARS) | after receiving Placebo or LDX for 1 week | T score | MEAN | |
| PRIMARY | Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | after receiving Placebo or LDX for 1 week | T score | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Conners Adult ADHD Rating Scale - Short Version (CAARS) | Placebo | 50.59 | Standard Deviation 10.975 | T score | |
| Conners Adult ADHD Rating Scale - Short Version (CAARS) | LDX 30-mg | 46.86 | Standard Deviation 9.939 | T score | |
| Conners Adult ADHD Rating Scale - Short Version (CAARS) | LDX 50-mg | 47.32 | Standard Deviation 10.092 | T score | |
| Conners Adult ADHD Rating Scale - Short Version (CAARS) | LDX 70-mg | 45.36 | Standard Deviation 10.790 | T score | |
| Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | Placebo | 65.91 | Standard Deviation 13.023 | T score | |
| Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | LDX 30-mg | 59.23 | Standard Deviation 14.088 | T score | |
| Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | LDX 50-mg | 57.64 | Standard Deviation 14.012 | T score | |
| Behavior Rating Inventory of Executive Function - Adult (BRIEF-A) | LDX 70-mg | 54.91 | Standard Deviation 13.219 | T score |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Healthy Controls | 26 | |
| Overall Study | STARTED | Attention-deficit/Hyperactivity Disorder (ADHD) Participants | 24 | |
| Overall Study | COMPLETED | Healthy Controls | 26 | |
| Overall Study | COMPLETED | Attention-deficit/Hyperactivity Disorder (ADHD) Participants | 22 | |
| Overall Study | NOT COMPLETED | Healthy Controls | 0 | |
| Overall Study | NOT COMPLETED | Attention-deficit/Hyperactivity Disorder (ADHD) Participants | 2 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Possible Heart Palpitations | Cardiac disorders | Placebo | 0 | 24 | 0 |
| other | Possible Heart Palpitations | Cardiac disorders | LDX 30-mg | 2 | 24 | 2 |
| other | Possible Heart Palpitations | Cardiac disorders | LDX 50-mg | 0 | 24 | 0 |
| other | Possible Heart Palpitations | Cardiac disorders | LDX 70-mg | 0 | 24 | 0 |
Source ClinicalTrials.gov
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | LDX 30-mg | ||
| Total, all-cause mortality | LDX 50-mg | ||
| Total, all-cause mortality | LDX 70-mg | ||
| Total, other adverse events | Placebo | 0 | 24 |
| Total, other adverse events | LDX 30-mg | 2 | 24 |
| Total, other adverse events | LDX 50-mg | 0 | 24 |
| Total, other adverse events | LDX 70-mg | 0 | 24 |
| Total, serious adverse events | Placebo | 0 | 24 |
| Total, serious adverse events | LDX 30-mg | 0 | 24 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22166471 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01342445
GET https://conductscience.org/api/trials/v1/NCT01342445/registered